Apolipoprotein A-I variant may clear atherosclerosis

January 2004
CMAJ: Canadian Medical Association Journal;1/6/2004, Vol. 170 Issue 1, p36
Academic Journal
Focuses on the results of a randomized controlled trial, which showed that apolipoprotein A-I variant may combat atherosclerosis. Characteristics of an individual possessing a naturally occurring variant of apolipoprotein A-I; Common notion about atherosclerotic plaques.


Related Articles

  • Acute Passivation of Vulnerable Plaques with Wild-Type Apolipoprotein A-I in ApoE-Deficient Mice. Laurberg, Jacob M.; Graversen, Jonas H.; Moestrup, Soren K.; Holmberg, Heidi L.; Falk, Erling // Vascular Disease Prevention;Oct2007, Vol. 4 Issue 4, p314 

    Objective: The apolipoprotein A-I (apoA-I) variant apoA-IMilano has rapid passivating effects on atherosclerotic plaques. In this study we tested if human wild-type apoA-I can likewise rapidly mobilize cholesterol and reduce inflammation and lipid contents of atherosclerotic plaques. Methods and...

  • Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice. Alexander, Matthew R.; Moehle, Christopher W.; Johnson, Jason L.; Zhengyu Yang; Lee, Jae K.; Jackson, Christopher L.; Owens, Gary K. // Journal of Clinical Investigation;Jan2012, Vol. 122 Issue 1, p70 

    Clinical complications of atherosclerosis arise primarily as a result of luminal obstruction due to atherosclerotic plaque growth, with inadequate outward vessel remodeling and plaque destabilization leading to rupture. IL-1 is a proinflammatory cytokine that promotes atherogenesis in animal...

  • Plaque-associated endothelial dysfunction in apolipoprotein E-deficient mice on a regular diet. Effect of human apolipoprotein AI Crauwels, Herta M.; Van Hove, Cor E.; Holvoet, Paul; Herman, Arnold G.; Bult, Hidde // Cardiovascular Research;Jul2003, Vol. 59 Issue 1, p189 

    Objective: Apolipoprotein E-deficient mice (apoE−/−) on a regular diet become hypercholesterolemic and develop atherosclerosis, but endothelium-dependent relaxation remains undisturbed for up to 6 months. We investigated whether vasomotor dysfunction develops in aged...

  • Rimonabant did not lower percent atheroma volume.  // Hem/Onc Today;5/10/2008, Vol. 9 Issue 8, p48 

    The article discusses on the results of the Strategy to Reduce Atherosclerosis Development Involving Administration of Rimonabant (STRADAVARIUS) trial that was presented by Dr. Steven E. Nissen at the American College of Cardiology 5th Annual Scientific Session. According to the study,...

  • Vytorin Failure Explained -- A New View of LDL. Peskin, Brian Scott; Sim, David // Townsend Letter;Jun2008, Issue 299, p101 

    The article discusses the clinical failure of the drug Vytorin based on the ENHANCE trial. The ENHANCE trial showed that the mean alteration in the intima-media thickness (IMT) between the effect of Zocor alone and Vytorin presented no statistical difference. IMT is regarded a descriptive...

  • Apolipoprotein E: Possible Therapeutic Target for Atherosclerosis. Bocksch, L.; Stephens, T.; Lucas, A.; Singh, B. // Current Drug Targets - Cardiovascular & Haematological Disorders;Dec2001, Vol. 1 Issue 2, p93 

    Human apolipoprotein E (apoE) consists of a single polypeptide chain with 299 amino acids and is best known for its role in the transport of cholesterol and other lipids between peripheral tissues and the liver. However, more direct effects of apoE on the vascular wall may well contribute to...

  • Pioglitazone cuts atherosclerosis risk in type-2 diabetes.  // GP: General Practitioner;4/4/2008, p4 

    The article reports on the efficacy of pioglitazone on lowering the rate of atherosclerosis in type-2 diabetics, based on the research conducted in the U.S. The results of the PERISCOPE trial showed that in a head-to-head trial, the drug was more effective in lowering the rate of progression of...

  • β-Blockers and Progression of Coronary Atherosclerosis: Pooled Analysis of 4 Intravascular Ultrasonography Trials. Sipahi, Ilke; Tuzcu, E. Murat; Wolski, Katherine E.; Nicholls, Stephen J.; Schoenhagen, Paul; Hu, Bo; Balog, Craig; Shishehbor, Mehdi; Magyar, William A.; Crowe, Timothy D.; Kapadia, Samir; Nissen, Steven E. // Annals of Internal Medicine;7/3/2007, Vol. 147 Issue 1, p10 

    Background: In patients with myocardial infarction, β-adrenergic blockers reduce recurrent myocardial infarction and total mortality rates. However, whether a direct influence of β-blockers on coronary atherosclerosis contributes to reduced recurrent myocardial infarction and total...

  • Notoginsenoside R1 Attenuates Atherosclerotic Lesions in ApoE Deficient Mouse Model. Jia, Chenglin; Xiong, Minqi; Wang, Peiwei; Cui, Jingang; Du, Xiaoye; Yang, Qinbo; Wang, Wenjian; Chen, Yu; Zhang, Teng // PLoS ONE;Jun2014, Vol. 9 Issue 6, p1 

    Aims: Atherosclerosis is the primary cause of cardiovascular diseases and stroke. The current study evaluated the interventional effects of a naturally occurring compound Notoginsenoside R1 (NR1) on atherosclerosis in ApoE−/− mice. Methods and Results: The atherosclerotic lesion was...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics